{
    "id": 6287,
    "fullName": "IDH2 R140W",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "IDH2 R140W lies within the substrate binding region of the Idh2 protein (UniProt.org). R140W results in decreased conversion of isocitrate to alpha-ketoglutarate (alpha-KG) by Idh2, and also results in increased conversion of alpha-KG to 2HG (R(-)-2-hydroxyglutarate) in an in vitro assay (PMID: 21647154), and therefore is predicted to confer a gain of function to Idh2.",
            "references": [
                {
                    "id": 9283,
                    "pubMedId": 21647154,
                    "title": "IDH1 and IDH2 mutations in pediatric acute leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21647154"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3418,
        "geneSymbol": "IDH2",
        "terms": [
            "IDH2",
            "D2HGA2",
            "ICD-M",
            "IDH",
            "IDHM",
            "IDP",
            "IDPM",
            "mNADP-IDH"
        ]
    },
    "variant": "R140W",
    "createDate": "05/17/2015",
    "updateDate": "10/16/2018",
    "referenceTranscriptCoordinates": {
        "id": 91608,
        "transcript": "NM_002168",
        "gDna": "chr15:g.90088703G>A",
        "cDna": "c.418C>T",
        "protein": "p.R140W",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17414,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176) with a median response duration of 5.8 months, complete remission in 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498) and IDH2 R140W is on the companion diagnostic.",
            "molecularProfile": {
                "id": 6137,
                "profileName": "IDH2 R140W"
            },
            "therapy": {
                "id": 2982,
                "therapyName": "Enasidenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9651,
                    "pubMedId": 28588020,
                    "title": "Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28588020"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15478,
                    "pubMedId": null,
                    "title": "Idhifa (enasidenib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3593,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Enasidenib (AG-221) and Quizartinib (AC220) stimulated leukemic cell differentiation and reduced leukemic cell self-renewal in an acute myeloid leukemia mouse model simultaneously expressing IDH2 R140Q and a FLT3-ITD mutation (Blood Dec 2014, 124 (21) 437).",
            "molecularProfile": {
                "id": 13759,
                "profileName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY IDH2 R140W"
            },
            "therapy": {
                "id": 3172,
                "therapyName": "Enasidenib + Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3871,
                    "pubMedId": null,
                    "title": "AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo",
                    "url": "http://www.bloodjournal.org/content/124/21/437?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6137,
            "profileName": "IDH2 R140W",
            "profileTreatmentApproaches": [
                {
                    "id": 16899,
                    "name": "IDH Inhibitor (Pan)",
                    "profileName": "IDH2 R140W"
                },
                {
                    "id": 16900,
                    "name": "IDH2 Inhibitor",
                    "profileName": "IDH2 R140W"
                }
            ]
        },
        {
            "id": 13759,
            "profileName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY IDH2 R140W",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 91608,
            "transcript": "NM_002168",
            "gDna": "chr15:g.90088703G>A",
            "cDna": "c.418C>T",
            "protein": "p.R140W",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}